Peptides - For research use only
New
Retatrutide 20 mg
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Body weight reduction of up to 24% in Phase II trials; the most potent in its class.
- Greater reduction in body fat compared to tirzepatide.
- Improved glycemic control through multiple mechanisms.
- Improvement in cardiovascular risk factors.
- Potential for treating NASH and reducing liver fat.
New
Selank
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Rapid anxiolytic effect without sedation or dependence.
- Cognitive improvement: memory consolidation and processing speed.
- Mood stabilization and resilience to stress.
- Modulation of the immune system through tuftsin activity.
- Minimal side effects compared to benzodiazepines.
- Used clinically in Russia to treat anxiety and cognitive disorders.
New
Semaglutide
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Average body weight reduction of 15–17% with 2.4 mg per week.
- A 1.5–2.0% reduction in HbA1c.
- A 20% reduction in MACE in the SELECT trial among an obese, non-diabetic population.
- Remission of NASH in clinical trials.
- Reduced cravings for substances and alcohol, according to emerging data.
- Potential cognitive protection in dementia research.
New
Semax
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Cognitive improvement: memory, attention, and processing speed.
- Neuroprotection in stroke, traumatic brain injury, and cerebral ischemia.
- Upregulation of BDNF/NGF for neuroplasticity.
- Anxiolytic and antidepressant properties.
- Immune modulation.
- Excellent safety profile: non-addictive and with minimal side effects.
New
SLU-PP-332
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Exercise mimicry: metabolic adaptations without physical exertion.
- Improved mitochondrial density and respiratory capacity.
- Increased endurance and fat oxidation.
- Potential effects on muscle aging and atrophy.
- Prevention of metabolic disease without the need for exercise.
- Synergy with AICAR for a comprehensive simulation of exercise.
Snap-8
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Non-invasive wrinkle reduction equivalent to botulinum toxin, though gentler and safer.
- Reduction in the depth of dynamic wrinkles on the forehead, crow's feet, and glabellar lines.
- Used in conjunction with Matrixyl and GHK-Cu in comprehensive anti-aging regimens.
- Active ingredient for cosmetic formulations or injectable administration.
- The preferred alternative for patients seeking options that do not involve botulinum toxin.
SS-31
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Restoration of mitochondrial function in aged and diseased tissues.
- Improved cardiac function in heart failure.
- Renal protection in ischemia-reperfusion injury.
- Reduction of neuroinflammation.
- Preservation of Muscle Fiber in Aging and Sarcopenia.
- FDA Breakthrough Therapy Designation for Barth Syndrome.
New
TB500
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Systemic repair and regeneration of soft tissues.
- Accelerated wound healing and scar reduction.
- Improved tissue flexibility and reduced inflammation.
- Cardiac protection and myocardial repair.
- Eye repair in research on corneal regeneration.
- Protection of renal podocytes.
New
Tesamorelin
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- FDA Approves Treatment to Reduce Visceral Fat Associated with HIV.
- Significant reduction in visceral fat in clinical trials.
- Improvement in lipid profile and metabolic health.
- Preservation of GH's natural pulsatile physiology.
- Cognitive Benefits: IGF-1 Modulation in Research on Mild Cognitive Impairment.
New
Thymosin Alpha-1
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Restoration of T-cell immunity in immunocompromised patients.
- Reduction of viral load in hepatitis B and C.
- Adjunctive use in HIV, cancer immunotherapy, and sepsis.
- Improving the immune response to vaccines in older adults.
- Anti-inflammatory action through immune balance and Th1/Th2 regulation.
- Adjunctive use in COVID-19, with significant evidence from China and Italy.
New
Tirzepatide
FOR PRECLINICAL RESEARCH USE ONLY — NOT APPROVED FOR HUMAN USE.
- Body weight reduction of up to 22.5% in SURMOUNT-1.
- A 2.0–2.3% reduction in HbA1c in the SURPASS program.
- Superior glycemic control compared with semaglutide in a direct comparative trial.
- Reduction in triglycerides and LDL.
- Improvement in sleep apnea in the SURMOUNT-OSA trial.
- Approved by the FDA for T2DM as Mounjaro and for obesity as Zepbound.
